Citations

Clear

1417 citation(s) found for "Li, Simon".

Systemic and Forearm Triglyceride Metabolism
Miles, John M., Park, Yongsoon , Walewicz, Dorota, Russell-Lopez, Crystal, Windsor, Sheryl L. , Isley, William L., Coppack, Simon W., Miles, John M., Harris, William Stephen

Mayo Clinic

Diabetes | March 6, 2007 | Volume: 53 | Issue: 3 | Pages: 521-527

10.2337/diabetes.53.3.521 | PMID 14988233 Get It

Little is known about the fate of the lipolytic products produced by the action of lipoprotein lipase (LPL) on circulating triglyceride-rich lipoproteins in humans. We studied eight lean, healthy male subjects after an overnight fast. Subjects received infusions of lipid emulsions containing triolein labeled with 3H on both the glycerol backbone and the fatty acid portion of the molecule; 14C glycerol and 14C oleate were coinfused to quantify the systemic and forearm release of 3H glycerol and 3H oleate resulting from LPL action. There was significant forearm uptake of both whole plasma triglyceride (presumed to represent primarily VLDL; extraction fraction 2.6 ± 0.6%, P < 0.005 vs. zero) and radiolabeled triglyceride derived from the lipid emulsion (a surrogate for chylomicrons; extraction fraction 31 ± 4%, P < 0.005 vs zero). Systemic clearance and forearm fractional extraction of glycerol was greater than that of oleate (P < 0.001 and P < 0.02, respectively). The systemic and forearm fractional release of LPL-generated glycerol were similar at 51 ± 4 and 59 ± 1%, respectively (NS). In contrast, the forearm fractional release of LPL-generated oleate was less than systemic fractional release (14 ± 2 vs. 36 ± 4%, P < 0.0001). These results indicate that there is escape, or spillover, of the lipolytic products of LPL action on triglyceride-rich lipoproteins in humans. They further suggest that LPL-mediated fatty acid uptake is an inefficient process, but may be more efficient in muscle than in adipose tissue.
Inhibition of Cholesterol Crystal Formation by Apolipoproteins in Supersaturated Model Bile
Kibe, A, Holzbach, Rüdiger , Mao, Simon J.T., LaRusso, Nicholas F.

Mayo Clinic

Science | October 5, 2006 | Volume: 225 | Issue: 4661 | Pages: 514-516

10.1126/science.6429856 | PMID 6429856 Get It

Apolipoproteins A-1 and A-2 were purified from human plasma. At concentrations present in human bile these proteins prolonged the nucleation time of cholesterol monohydrate crystals when added to model systems of supersaturated bile. In contrast, apolipoprotein C-3 and other serum proteins did not have this effect. Also, when human gallbladder bile was fractionated by gel filtration chromatography, apolipoproteins A-1 and A-2 were among the proteins present in a fraction of bile enriched in potent inhibitors of cholesterol crystal nucleation. These findings suggest that apolipoproteins A-1 and A-2 in supersaturated human gallbladder bile could inhibit the rate of formation of solid cholesterol crystals and thus help to prevent spontaneous cholesterol gallstone formation in humans.
Role of Low Levels of Endogenous Estrogen in Regulation of Bone Resorption in Late Postmenopausal Women
Heshmati, Hassan , O’Fallon, W. Michael, Melton, L. Joseph, Riggs, B. Lawrence, Khosla, Sundeep , Robins, Simon P.

Mayo Clinic

Journal of Bone and Mineral Research | April 27, 2006 | Volume: 17 | Issue: 1 | Pages: 172-178

10.1359/jbmr.2002.17.1.172 | PMID 11771665 Get It

Abstract Although median levels of bone turnover are increased in postmenopausal women, it is unclear whether the low circulating levels of endogenous estrogen exert a regulatory role on these levels. This issue was evaluated by assessing the effect of a blockade of estrogen synthesis on bone turnover markers in 42 normal women (mean age ± SD, 69 ± 5 years) randomly assigned to groups receiving the potent aromatase inhibitor letrozole or placebo for 6 months. Letrozole treatment reduced serum estrone (E1) and estradiol (E2) to near undetectable levels (p < 0.0001). This treatment did not affect bone formation markers but, as compared with the placebo group, increased bone resorption markers (urine 24-h pyridinoline [PYD] by 13.3% [p < 0.05] and 24-h urine deoxypyridinoline [DPD] by 14.2% [p < 0.05]) and decreased serum parathyroid hormone (PTH) by 22% (p = 0.002). These data indicate that in late postmenopausal women even the low serum estrogen levels present exert a restraining effect on bone turnover and support the concept that variations in these low levels may contribute to differences in their rate of bone loss.
Lymphocyte Activation Antigen CD70 Expressed by Renal Cell Carcinoma Is a Potential Therapeutic Target for Anti-CD70 Antibody-Drug Conjugates
Gordon, Kristine A., Toki, Brian E., Yamane, Andrew K., Hering, Michelle A., Cerveny, Charles G., Petroziello, Joseph M., Ryan, Maureen C. , Smith, Leia M., Simon, Ronald , Sauter, Guido , Oflazoglu, Ezogelin, Doronina, Svetlana O., Meyer, Damon L., Francisco, Joseph A., Senter, Peter D. , Copland, John A. , Wood, Christopher G. , Wahl, Alan F., Law, Che‐Leung , Carter, Paul

Mayo Clinic

Cancer Research | February 17, 2006 | Volume: 66 | Issue: 4 | Pages: 2328-2337

10.1158/0008-5472.can-05-2883 | PMID 16489038 Get It

AbstractMetastatic renal cell carcinoma (RCC) is an aggressive disease refractory to most existing therapeutic modalities. Identifying new markers for disease progression and drug targets for RCC will benefit this unmet medical need. We report a subset of clear cell and papillary cell RCC aberrantly expressing the lymphocyte activation marker CD70, a member of the tumor necrosis factor superfamily. Importantly, CD70 expression was found to be maintained at the metastatic sites of RCC. Anti-CD70 antibody-drug conjugates (ADC) consisting of auristatin phenylalanine phenylenediamine (AFP) or monomethyl auristatin phenylalanine (MMAF), two novel derivatives of the anti-tubulin agent auristatin, mediated potent antigen-dependent cytotoxicity in CD70-expressing RCC cells. Cytotoxic activity of these anti-CD70 ADCs was associated with their internalization and subcellular trafficking through the endosomal-lysosomal pathway, disruption of cellular microtubule network, and G2-M phase cell cycle arrest. The efficiency of drug delivery using anti-CD70 as vehicle was illustrated by the much enhanced cytotoxicity of antibody-conjugated MMAF compared with free MMAF. Hence, ADCs targeted to CD70 can selectively recognize RCC, internalize, and reach the appropriate subcellular compartment(s) for drug release and tumor cell killing. In vitro cytotoxicity of these ADCs was confirmed in xenograft models using RCC cell lines. Our findings provide evidence that CD70 is an attractive target for antibody-based therapeutics against metastatic RCC and suggest that anti-CD70 ADCs can provide a new treatment approach for advanced RCC patients who currently have no chemotherapeutic options. (Cancer Res 2006; 66(4): 2328-37)
CORPOREAL STRUCTURAL AND VASCULAR MICRO ARCHITECTURE WITH X-RAY MICRO COMPUTERIZED TOMOGRAPHY IN NORMAL AND DIABETIC RABBITS: HISTOPATHOLOGICAL CORRELATION
Simopoulos, Demetrios N. , Malysz, John , Szurszewski, Joseph H., Farrugia, Gianrico , Ritman, Erik L., Moreland, Robert B. , Nehra, Ajay, Gibbons, Simon J.

Mayo Clinic

Journal of Urology | January 18, 2006 | Volume: 165 | Issue: 5 | Pages: 1776-1782

10.1016/s0022-5347(05)66413-0 Get It

POTASSIUM OUTWARD CURRENTS IN FRESHLY DISSOCIATED RABBIT CORPUS CAVERNOSUM MYOCYTES
Malysz, John , Gibbons, Simon J. , Gettman, Matthew T., Nehra, Ajay, Szurszewski, Joseph H., Farrugia, Gianrico , Miller, Steven , Gibbons, S J

Mayo Clinic

Journal of Urology | January 18, 2006 | Volume: 166 | Issue: 3 | Pages: 1167-1177

10.1016/s0022-5347(05)65940-x Get It

Implications of the serine protease HtrA1 in amyloid precursor protein processing
Grau, Sandra, Baldi, Alfonso , Bussani, Rossana , Tian, Xiaodan, Ştefănescu, Raluca , Przybylski, Michael , Richards, Peter J. , Jones, Simon A. , Shridhar, Viji , Clausen, Tim , Ehrmann, Michael , Dichgans, Martin , Dichgans, Martin

Mayo Clinic

Proceedings of the National Academy of Sciences | April 26, 2005 | Volume: 102 | Issue: 17 | Pages: 6021-6026

10.1073/pnas.0501823102 | PMID 15855271 Get It

The defining features of the widely conserved HtrA (high temperature requirement) family of serine proteases are the combination of a catalytic protease domain with one or more C-terminal PDZ domains and reversible zymogen activation. Even though HtrAs have previously been implicated in protein quality control and various diseases, including cancer, arthritis, and neuromuscular disorder, the biology of the human family members is not well understood. Our data suggest that HtrA1 is directly involved in the β-amyloid pathway as it degrades various fragments of amyloid precursor protein while an HtrA1 inhibitor causes accumulation of Aβ in astrocyte cell culture supernatants. Furthermore, HtrA1 colocalizes with β-amyloid deposits in human brain samples. Potential implications in Alzheimer's disease are discussed.
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma
Kumar, Shaji , Hideshima, Teru , Roccaro, Aldo M. , Ishitsuka, Kenji , Yasui, Hiroshi , Shiraishi, Norihiko, Chauhan, Dharminder , Munshi, Nikhil C. , Green, Simon R. , Raje, Noopur , Anderson, Kenneth C. , Roccaro, Aldo M

Mayo Clinic

Blood | April 13, 2005 | Volume: 106 | Issue: 3 | Pages: 1042-1047

10.1182/blood-2005-01-0320 | PMID 15827128 Get It

AbstractCyclin-dependent kinase (CDK) inhibitors have the potential to induce cell-cycle arrest and apoptosis in cancer cells. Seliciclib (CYC202 or R-roscovitine) is a potent CDK inhibitor currently undergoing phase-2 clinical testing in lung and B-cell malignancies. Here we studied the in vitro cytotoxic activity of seliciclib against multiple myeloma (MM) cells. Our data demonstrate that seliciclib has potent cytotoxicity against MM cells that are both sensitive and resistant to conventional therapy as well as primary MM cells from patients. Cell-cycle and Western blot analysis confirmed apoptosis. Importantly, seliciclib triggered a rapid down-regulation of Mcl-1 transcription and protein expression independent of caspase cleavage. Adherence of MM cells to bone marrow stromal cells (BMSCs) induced increased Mcl-1 expression associated with signal transducer and activator of transcription 3 (STAT3) phosphorylation, which was inhibited in a time- and dose-dependent manner by seliciclib. Furthermore, seliciclib inhibited interleukin 6 (IL-6) transcription and secretion triggered by tumor cell binding to BMSCs. Up-regulation of Mcl-1 expression in cocultures was only partially blocked by neutralizing antibody to IL-6, suggesting alternative mechanisms of Mcl-1 modulation by seliciclib. Finally, combination studies of seliciclib with doxorubicin and bortezomib show in vitro synergism, providing the rationale for testing these drug combinations to improve patient outcome in MM.
TissueLink™ Device for Laparoscopic Nephron-Sparing Surgery
Stern, Jeffrey A., Simon, Scott D. , Ferrigni, Robert G., Andrews, Paul E.

Mayo Clinic

Journal of Endourology | October 22, 2004 | Volume: 18 | Issue: 5 | Pages: 455-456

10.1089/0892779041271463 | PMID 15253818 Get It

COMPLICATIONS OF LAPAROSCOPIC NEPHRECTOMY: THE MAYO CLINIC EXPERIENCE
Simon, Scott D. , Castle, Erik P., Ferrigni, Robert G., Lamm, Donald L. , Swanson, Scott K., Novicki, Donald E., Andrews, Paul E.

Mayo Clinic

Journal of Urology | August 25, 2004 | Volume: 171 | Issue: 4 | Pages: 1447-1450

10.1097/01.ju.0000117942.61971.41 | PMID 15017195 Get It